Background
Panion Animal Health is a veterinary drug company; the company’s business idea is to develop medicines and treatment methods that create a better life for animals.

The first product Panion chose to develop is a preparation for the treatment of epilepsy in dogs under a licensing agreement with CombiGene. CombiGene has recently published successful studies on dose- response and long- term effects in rats. In addition, Panion has safety data from two dog studies.

Panion has come a long way in preparing for the first efficacy study (Pilot Study). This study is planned to be conducted in North America in the spring (-19). Panion has opened an INAD file with the US-FDA. In the EU, Panion has met with the Innovation Task Force of the European Medicines Agency (EMA). The company cooperates with both the FDA and EMA so that research and development is in line with authority advice and recommendations, to minimize risks in the forthcoming pilot study.

Motivation for the issue
The motivation for the new share issue is to ensure the upcoming pilot study in the United States. There are currently different options available for future financing. By offering existing owners the opportunity to participate, we give existing owners the same terms as may be offered to external financiers.

Investor meeting
Panion’s CEO, Anja Holm, will hold an investor meeting at Mangold’s premises in Stockholm on 14 December. Anja will describe Panion’s activities and ongoing research in gene therapy for the treatment of epilepsy-like conditions in dogs.

For registration to below, please email to: emissionstjanster@mangold.se

Date: December 14, 2018
Time: 12-13
Location:Engelbrektsplan 2, Stockholm (Mangolds office)

For more information, and all emission documents see:
panion-animalhealth.com/emission/
www.mangold.se/aktuella-emissioner
www.spotlightstockmarket.com

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet.
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases.